ArticleBlood2015
Azacitidine in AML: a treatment option?
Article in Blood, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine.Blood cancer journal · 2023Article
- Systematic Construction and Validation of a Metabolic Risk Model for Prognostic Prediction in Acute Myelogenous Leukemia.Frontiers in oncology · 2020Article
- Review
- Drug Shortage Impacts Patient Receipt of Induction Treatment.Health services research · 2018Article
- Review
- Clinical implications of genome-wide DNA methylation studies in acute myeloid leukemia.Journal of hematology & oncology · 2017Review
- [Modification of DNA methylation in leukemia development].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2016Article
- Physiological and pathological implications of 5-hydroxymethylcytosine in diseases.Oncotarget · 2016Review
- Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors.Immunotherapy · 2016Review
Corrections and comments
- Comment on
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this issue of Blood, Dombret et al report the final analysis of the international phase 3 study of azacitidine vs conventional care regimens in older (≥65 years), newly diagnosed acute myeloid leukemia (AML) patients with >30% bone marrow blasts and white blood cell (WBC) counts ≤15 × 109/L (AZA-AML-001 study).
Indexed as
Identifiers
26185114What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.